OncoMatch/Clinical Trials/NCT06577987
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Is NCT06577987 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CID-078 Monotherapy for advanced solid tumor.
Treatment: CID-078 Monotherapy — This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Neuroendocrine Tumor
Biomarker criteria
Required: RB1 genomic alteration
solid tumors harboring a RB1 genomic alteration
Required: RB1 protein loss of function
solid tumors harboring...Rb protein LoF
Required: CDKN2A genomic alteration
solid tumors harboring a...CDKN2A...genomic alteration
Required: CDKN2B genomic alteration
solid tumors harboring a...CDKN2B genomic alteration
Disease stage
Metastatic disease required
measurable disease per RECIST v1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all available therapies
has progressed or was non responsive to available therapies and for which no standard or available curative therapy exists
Cannot have received: CID-078 (CID-078)
Prior therapy with CID-078
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL (last transfusion > 14 days prior); Platelets ≥ 100 × 10^9 cells/L (last platelet transfusion > 14 days prior); ANC ≥ 1.2 × 10^9 cells/L (last dose of hematopoietic growth factors > 14 days prior)
Kidney function
CrCl ≥ 60 mL/min/1.73 m2 or eGFR ≥ 60 mL/min/1.73 m2; for patients < 18 years: serum creatinine within normal limits or eGFR ≥ 60 mL/min/1.73 m2
Liver function
Total bilirubin ≤ 1.5 × ULN unless prior history of Gilbert's syndrome with Sponsor Medical Monitor approval; AST/ALT ≤ 2.5 × ULN, or ≤ 5 × ULN if due to liver involvement by tumor
Cardiac function
QTc interval (Fridericia) ≤ 470 msec
See inclusion criteria 8 and exclusion criteria 8
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists · Sarasota, Florida
- Dana Farber Cancer Institute · Boston, Massachusetts
- START Midwest · Grand Rapids, Michigan
- Comprehensive Cancer Centers of Nevada · Las Vegas, Nevada
- UH Seidman Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify